SCHEMBL12955953

SCHEMBL12955953

CC(C)(C)c1ccc(SNc2cc(Cl)cnc2C(N)=O)cc1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ALDH1A1 P00352 3/20 0.39
▸ CCR9 P51686 4/20 0.38
▸ SMN1; SMN2 Q16637 3/20 0.37
▸ POLB P06746 1/20 0.37
▸ LRRK2 Q5S007 1/20 0.36
▸ IKBKB O14920 1/20 0.36
▸ GAA P10253 1/20 0.35
▸ HSD17B2 P37059 2/20 0.35
▸ SERPINE1 P05121 1/20 0.35
▸ NPC1 O15118 3/20 0.35
▸ RAB9A P51151 3/20 0.35
▸ PLAU P00749 1/20 0.34
▸ ELANE P08246 1/20 0.34
▸ LMNA P02545 2/20 0.33
▸ NPSR1 Q6W5P4 2/20 0.33
▸ HSP90AA1 P07900 1/20 0.33
▸ MAPT P10636 1/20 0.33
▸ THRB P10828 1/20 0.33
▸ KMT2A Q03164 1/20 0.33
▸ DHPS P49366 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14303218 0.82 CCR9 (0.33) ALDH1A1CCR9POLBGAAHSD17B2
SCHEMBL14303215 0.81 BACE1 (0.34) CCR9SMN1; SMN2NPC1RAB9AMAPT
SCHEMBL14303638 0.77 CCR9 (0.35) CCR9HSD17B2
SCHEMBL13908072 0.73 PLAU (0.36) CCR9SMN1; SMN2POLBGAASERPINE1
SCHEMBL13908074 0.71 LMNA (0.40) CCR9SMN1; SMN2GAANPC1RAB9A
SCHEMBL11938270 0.69 CCR9 (0.68) CCR9SMN1; SMN2POLBGAASERPINE1
SCHEMBL12703497 0.69 BRAF (0.59) —
SCHEMBL12161641 0.68 RAB9A (0.56) ALDH1A1SMN1; SMN2POLBGAASERPINE1
SCHEMBL11936681 0.68 CCR9 (0.53) CCR9SMN1; SMN2POLBSERPINE1LMNA
SCHEMBL11937065 0.68 CCR9 (0.52) CCR9GAASERPINE1NPC1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2049515-B1 TRIAZOLYL PYRIDYL BENZENESULFONAMIDES AS CCR2 OR CCR9 MODULATORS FOR THE TREATMENT OF ATHEROSCLEROSIS CHEMOCENTRYX INC (US) 2011-01-26 — — EP disclosed
Send feedback